HomeCompareSYK vs LRCX

SYK vs LRCX: Dividend Comparison 2026

SYK yields 1.04% · LRCX yields 0.51%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LRCX wins by $443.0K in total portfolio value· pulled ahead in Year 4
10 years
SYK
SYK
● Live price
1.04%
Share price
$326.10
Annual div
$3.40
5Y div CAGR
46.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.3K
Annual income
$8,282.98
Full SYK calculator →
LRCX
LRCX
● Live price
0.51%
Share price
$199.93
Annual div
$1.01
5Y div CAGR
97.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$486.3K
Annual income
$337,677.40
Full LRCX calculator →

Portfolio growth — SYK vs LRCX

📍 LRCX pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSYKLRCX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SYK + LRCX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SYK pays
LRCX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYK
Annual income on $10K today (after 15% tax)
$88.62/yr
After 10yr DRIP, annual income (after tax)
$7,040.53/yr
LRCX
Annual income on $10K today (after 15% tax)
$42.94/yr
After 10yr DRIP, annual income (after tax)
$287,025.79/yr
At 15% tax rate, LRCX beats the other by $279,985.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYK + LRCX for your $10,000?

SYK: 50%LRCX: 50%
100% LRCX50/50100% SYK
Portfolio after 10yr
$264.8K
Annual income
$172,980.19/yr
Blended yield
65.33%
📊

Analyst Conviction Gap

Where Wall Street is split right now

SYK
Analyst Ratings
1
Strong
35
Buy
14
Hold
Consensus: Buy
Price Target
$428.67
+31.5% upside vs current
Range: $390.00 — $469.00
Altman Z
4.0
Piotroski
5/9
LRCX
Analyst Ratings
38
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$267.50
+33.8% upside vs current
Range: $127.00 — $325.00
Altman Z
17.9
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYK buys
0
LRCX buys
4
PoliticianChamberTickerTypeAmountDate
David Taylor🏢 House$LRCX▲ Buy$1,001 - $15,0002026-03-12
David Taylor🏢 House$LRCX▼ Sell$1,001 - $15,0002026-02-26
David Taylor🏢 House$LRCX▼ Sell$1,001 - $15,0002026-02-26
Tony Wied🏢 House$LRCX▼ Sell$50,001 - $100,0002026-02-12
Tony Wied🏢 House$LRCX▼ Sell$50,001 - $100,0002026-02-09
Tony Wied🏢 House$LRCX▼ Sell$50,001 - $100,0002026-02-03
Cleo Fields🏢 House$LRCX▲ Buy$15,001 - $50,0002026-02-03
David Taylor🏢 House$LRCX▼ Sell$1,001 - $15,0002026-01-16
John Boozman🏛 Senate$LRCX▼ Sell$1,001 - $15,0002026-01-08
John Boozman🏛 Senate$LRCX▼ Sell$1,001 - $15,0002026-01-08
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSYKLRCX
Forward yield1.04%0.51%
Annual dividend / share$3.40$1.01
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR46.2%97.1%
Portfolio after 10y$43.3K$486.3K
Annual income after 10y$8,282.98$337,677.40
Total dividends collected$21.0K$453.2K
Payment frequencyquarterlyquarterly
SectorHealthcareTechnology
Analyst consensusBuyBuy
Analyst price target$428.67$267.50

Year-by-year: SYK vs LRCX ($10,000, DRIP)

YearSYK PortfolioSYK Income/yrLRCX PortfolioLRCX Income/yrGap
1$10,852$152.43$10,800$99.57+$52.00SYK
2$11,838$226.03$11,754$198.08+$84.00SYK
3$13,004$336.89$12,973$397.11+$31.00SYK
4← crossover$14,420$505.63$14,689$807.41$269.00LRCX
5$16,195$766.09$17,401$1,683.97$1.2KLRCX
6$18,504$1,175.64$22,294$3,674.72$3.8KLRCX
7$21,635$1,835.40$32,527$8,672.33$10.9KLRCX
8$26,082$2,932.10$58,111$23,307.38$32.0KLRCX
9$32,737$4,829.68$138,882$76,703.10$106.1KLRCX
10$43,312$8,282.98$486,281$337,677.40$443.0KLRCX

SYK vs LRCX: Complete Analysis 2026

SYKHealthcare

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

Full SYK Calculator →

LRCXTechnology

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products. It also provides SPEED gapfill high-density plasma chemical vapor deposition products; and Striker single-wafer atomic layer deposition products for dielectric film solutions. In addition, the company offers Flex for dielectric etch applications; Kiyo for conductor etch applications; Syndion for through-silicon via etch applications; and Versys metal products for metal etch processes. Further, it provides Coronus bevel clean products to enhance die yield; Da Vinci, DV-Prime, EOS, and SP series products to address various wafer cleaning applications; and Metryx mass metrology systems for high precision in-line mass measurement in semiconductor wafer manufacturing. The company sells its products and services to semiconductors industry in the United States, China, Europe, Japan, Korea, Southeast Asia, Taiwan, and internationally. Lam Research Corporation was incorporated in 1980 and is headquartered in Fremont, California.

Full LRCX Calculator →
📬

Get this SYK vs LRCX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYK vs SCHDSYK vs JEPISYK vs OSYK vs KOSYK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.